This is an aggregated industry headline. Read the full story at BioPharma Dive →
Agios scraps sickle cell drug
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that's frustrated drugmakers of late.
By BioPharma Dive
· Jul 21, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Amgen has agreed to a $74 million settlement with investors to resolve a lawsuit that alleged the company hid …
The WeekFierceBiotech ↗
A rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-k…
The WeekBriefing
Novo Nordisk filed suit against Eli Lilly over GLP‑1 drugs as Anthropic deepened its rare‑disease biotech work…